Insta
Johnson & Johnson's Single-Dose COVID-19 Vaccine Approved For Use In European Union
Swarajya Staff
Mar 12, 2021, 11:04 AM | Updated 11:04 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
The European Union (EU) has approved the use of the single-dose COVID-19 vaccine developed by the United States (US) based pharmaceutical major Johnson & Johnson (J&J), reports Economic Times.
This makes J&J's vaccine the fourth jab to have been approved for administration in the 27 nations which are part of the EU. The other approved vaccines include those developed by Pfizer-BioNTech, Moderna and AstraZeneca-Oxford.
The latest approval to J&J vaccine is likely to give a boost to the block's vaccination programme, even though the first shipments of J&J doses may not arrive in European countries until April.
European Medicines Agency (EMA), the EU drug regulator, noted that the clinical trials involving volunteers in the United States, South Africa and South American countries found the Johnson & Johnson vaccine was 67 per cent effective at preventing people from getting COVID-19.
EMA also observed that the side effects were observed to be "usually mild or moderate" which cleared within a couple of days, including pain at the injection site, headache, tiredness, muscle pain and nausea.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.